Article Per Year (5 Year)
p-Index From 2020 - 2025
0.562
P-Index
This Author published in this journals
All Journal Molecular and Cellular Biomedical Sciences (MCBS) Cermin Dunia Kedokteran Jurnal MedScientiae
Rosdiana, Dewi Selvina
Department Of Pharmacology & Therapeutic, Faculty Of Medicine University Of Indonesia
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
The Efficacy and Safety of Two Depo Medroxyprogesterone Acetate Injection Preparations as Contraception: An Open-Label, Randomized Controlled Study Rosdiana, Dewi Selvina; K. Suherman, Suharti; Affandi, Biran; Gunadi, E. Rusdianto; Amelia, Dwirani; Baharrudin, Mohammad
Cermin Dunia Kedokteran Vol 44, No 5 (2017): Gastrointestinal
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (250.93 KB) | DOI: 10.55175/cdk.v44i5.794

Abstract

Latar belakang: Kontrasepsi hormonal injeksi masih banyak digunakan di berbagai negara berkembang, termasuk di Indonesia. Tujuan penelitian ini adalah untuk membandingkan efikasi dan keamanan kontrasepsi hormonal injeksi mengandung 150 mg/mL medroxyprogesterone acetate (DMPA) (obat A) yang akan digunakan untuk program Keluarga Berencana Nasional, dibandingkan dengan inovatornya (obat B). Metode: penelitian ini open-label, acak, multisenter, 2 kelompok, melibatkan 400 subjek usia produktif, yang diacak untuk mendapatkan obat A atau obat B. Injeksi diberikan sekali setiap 3 bulan, selama 1 tahun. Hasil: Setelah 4 kali injeksi kontrasepsi periode satu tahun, tidak didapatkan kehamilan pada kedua kelompok, nilai Pearl-Index masing-masing kelompok nol. Insidensi kejadian tidak diinginkan sebanding pada kedua kelompok dan dapat ditoleransi, dengan kejadian paling sering adalah amenore, spotting, sakit kepala dan menstruasi memanjang. Simpulan: Kontrasepsi hormonal injeksi yang akan digunakan untuk program KB nasional (obat A) memiliki efikasi dan keamanan yang sebanding dengan inovatornya (obat B).Backgroud: Injectable hormonal contraceptives remain in extensive use in many developing countries, including Indonesia. This study was intended to compare the efficacy and safety of injectable hormonal contraception contain 150 mg/mL DMPA injection (Drug A), that will be used for national Family Planning Program, versus the innovator product (Drug B). Methods: This study was an open-label, randomized, multicenter, 2-parallel group study, involving 400 women of childbearing age, who received Drug A or Drug B four times at 3-month intervals. Results: No pregnancies occur in both groups after 4 injections of Drug A or Drug B over a period of 12 months, the Pearl-Index value for each group was zero. The incidence of adverse events between groups were comparable and tolerable, the most common events were amenorrhea, spotting, headache, and prolonged menstruation. Conclusion: The efficacy and safety of injectable DMPA (Drug A) produced for National Family Planning program was comparable with the innovator DMPA drug (Drug B).
The Prospect of Probiotics to Treat Metabolic Syndrome Ramadhan, Andika Yusuf; Rosdiana, Dewi Selvina
Molecular and Cellular Biomedical Sciences Vol 8, No 2 (2024)
Publisher : Cell and BioPharmaceutical Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21705/mcbs.v8i2.425

Abstract

Metabolic syndrome remains as a major health problem in the world today, with a prevalence of 23.4% in people aged 26-82 years. A high-fat, high-carbohydrate diet and lack of physical activity are considered as one of the triggers for metabolic syndrome. Dysbiosis is a condition where there is an imbalance between pathogenic and non-pathogenic bacteria in the human gut. Currently, an association has been found between dysbiosis and metabolic syndrome. Dysbiosis causes the generation of fermentation products in the form of active metabolites that can modulate hormones and other physiological functions. In metabolic syndrome, low-grade inflammation, energy metabolism, and disruption of the gut brain axis are thought to be the main mechanisms of the development of metabolic syndrome due to dysbiosis. Probiotics may be a promising therapeutic agent in the treatment of metabolic syndrome, by improving dysbiosis to eubiosis. Based on previously conducted clinical trials, it is currently known that probiotics can improve lipid profiles, fasting blood glucose, homeostatic model assessment for insulin resistance (HOMA-IR), vascular cell adhesion molecule 1 (VCAM-1), glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and body mass index (BMI). However, the results found are still varied, so a dose ranging study is needed to determine the duration, bacterial composition and dose of probiotics as a therapeutic agent for metabolic syndrome. Keywords: insulin resistance, dysbiosis, gut-brain axis
Inhibitor Transient Receptor Potential Vanilloid Type 1: Penggunaan Topikal pada Berbagai Dermatosis Muhammad, Parikesit; Paramitha Wibawa, Larisa; Keumala Budianti, Windy; Legiawati, Lili; Menaldi, Sri Linuwih; Rosdiana, Dewi Selvina
Jurnal MedScientiae Vol. 3 No. 2 (2024): Agustus
Publisher : Universitas Kristen Krida Wacana

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36452/JMedScientiae.v3i2.3179

Abstract

Transient receptor potential vanilloid type 1 (TRPV1) plays an important role in the pathophysiology of pruritus and pain. TRPV1 inhibitors can reduce the sensation of itching and pain by blocking nociceptive signals from peripheral nerve fibers to the central nervous system. Topical TRPV1 inhibitors is also thought to improve skin barrier function. Therefore, TRPV1 inhibitors are considered as potential therapy in various dermatoses. Topical TRPV1 inhibitors that are currently being studied are asivatrep for atopic dermatitis and trans-4-tert-butylcyclohexanol for various dermatoses associated with sensitive skin. Further studies with better quality and longer duration are needed to assess the efficacy and safety profile of TRPV1 inhibitors.
Co-Authors Aisyah, Syarifah Amelia, Dwirani Baharrudin, Mohammad Biran Affandi Gunadi, E. Rusdianto K. Suherman, Suharti Keumala Budianti, Windy Larisa Paramitha Lili Legiawati Muhammad, Parikesit Ramadhan, Andika Yusuf Sri L. Menaldi Sulthany, Ade Ichwan